To identify the potential molecular mechanism responsible for the effect on CuraUltrad treat-ment, label-free quantitative proteomics by tandem mass spectrometry (LC-MS/MS) were per-formed, which provides in depth characterization of protein profile changes. Critical altered proteins were validated by qPCR and Western blotting.